Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen in South Korea

Cardium Therapeutics

today announced that it has entered into its first international agreement for the commercialization of Excellagen in the South Korean market. Cardium entered into a marketing and distribution agreement with BL&H Co. Ltd., an established pharmaceutical company based in Korea, for the commercialization of Excellagen Formulated Fibrillar Collagen Gel in the South Korean market under a transfer price arrangement as further described below.